

1 **A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2,**
2 **despite low post-exposure prophylaxis efficacy and frequent viral rebound**
3

4
5 **Authors**

6 Shadisadat Esmaeili,^{1*} Katherine Owens,^{1†} Jessica Wagoner,² Stephen J. Polyak,² Judith M.
7 White,³ Joshua T. Schiffer^{1,2}
8

9 **Affiliations**

10 ¹Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA.

11 ²Department of Medicine, University of Washington; Seattle, WA, USA.

12 ³Department of Cell Biology, University of Virginia; Charlottesville, VA, USA.

13 *Corresponding Author: sesmaeil@fredhutch.org

14 † These authors contributed equally to this work.
15

16 **Abstract**

17 In a pivotal trial (EPIC-HR), a 5-day course of oral ritonavir-boosted nirmatrelvir, given early
18 during symptomatic SARS-CoV-2 infection (within three days of symptoms onset), decreased
19 hospitalization and death by 89.1% and nasal viral load by 0.87 log relative to placebo in high-
20 risk individuals. Yet, nirmatrelvir/ritonavir failed as post-exposure prophylaxis in a trial, and
21 frequent viral rebound has been observed in subsequent cohorts. We developed a mathematical
22 model capturing viral-immune dynamics and nirmatrelvir pharmacokinetics that recapitulated
23 viral loads from this and another clinical trial (PLATCOV). Our results suggest that
24 nirmatrelvir's *in vivo* potency is significantly lower than *in vitro* assays predict. According to
25 our model, a maximally potent agent would reduce the viral load by approximately 3.5 logs
26 relative to placebo at 5 days. The model identifies that earlier initiation and shorter treatment
27 duration are key predictors of post-treatment rebound. Extension of treatment to 10 days for
28 Omicron variant infection in vaccinated individuals, rather than increasing dose or dosing
29 frequency, is predicted to lower the incidence of viral rebound significantly.
30
31

32 Introduction

33 The SARS-CoV-2 main protease inhibitor nirmatrelvir is a drug plagued by
34 contradictions. In a landmark, randomized, double-blinded, placebo-controlled clinical
35 trial with 1364 analyzed individuals, 300 mg of nirmatrelvir boosted with 100 mg
36 ritonavir was given twice daily for five days to high-risk individuals with SARS-CoV-2
37 infection within 3 days of developing symptoms. Compared to placebo, nirmatrelvir
38 reduced the combined outcome of hospitalization and death by 89%, eliminated death
39 as an outcome, and reduced viral load by 0.87 log after 5 days of treatment¹. This
40 critical result prompted the Food and Drug Administration (FDA) to issue an
41 Emergency Use Authorization². The drug became the most widely prescribed antiviral
42 for SARS-CoV-2 in the United States, likely preventing thousands of hospitalizations
43 and many deaths³. Ritonavir boosted nirmatrelvir was recently licensed by the FDA
44 based on its continued effectiveness and safety⁴ and has outperformed other antivirals
45 in terms of hospitalization and viral load reduction⁵.

46 However, the use of nirmatrelvir/ritonavir in real-world cohorts has identified viral
47 rebound as a significant issue. Viral rebound occurred in 14.2% of individuals in one
48 large cohort and was usually associated with recrudescence of symptoms, though
49 protection against hospitalization and death appeared to be maintained⁶ and remains
50 significant despite high rates of population immunity due to vaccination and prior
51 infection⁷. Similar rates of viral rebound were observed between molnupiravir and
52 nirmatrelvir, suggesting the rebound effect is not drug-specific and may pertain to
53 characteristics of SARS-CoV-2 infection and treatment duration⁸. This high incidence
54 of viral rebound exceeded the 2.3% rate observed in the proof-of-concept trial, which
55 did not differ from placebo⁹.

56 Despite its high efficacy as an early symptomatic therapy for high-risk individuals,
57 nirmatrelvir/ritonavir was not authorized for use as post-exposure prophylaxis (PEP). In
58 a clinical trial of post-exposure prophylaxis, nirmatrelvir/ritonavir showed 32% and
59 37% reductions in symptomatic COVID-19 relative to placebo when given for five or
60 ten days respectively¹⁰. However, neither of these results reached statistical
61 significance. Notably, molnupiravir, another drug that reduced hospitalization when
62 given during early symptomatic infection, also failed as post-exposure prophylaxis¹¹.
63 Only long-acting monoclonal antibodies have demonstrated efficacy for post-exposure
64 prophylaxis¹²⁻¹⁴, but these are no longer active against prevalent circulating strains¹⁵.

65 Early during the COVID-19 pandemic, multiple groups employed mathematical models
66 to simulate the outcomes of clinical trials for SARS-CoV-2¹⁶⁻²². These models all
67 accurately predicted that antiviral therapy that was insufficiently potent or given too
68 late during infection might fail to provide clinical benefit^{16-19,21}. Our previous modeling
69 results further suggested that viral rebound may occur and was more likely if a drug
70 was dosed during the pre-symptomatic phase of infection when viral loads are still
71 expanding, as occurs in a post-exposure prophylaxis scenario²³. The proposed
72 mechanism of this effect was that reducing viral load may blunt early immune
73 responses and preserve susceptible cells, allowing viral re-expansion upon cessation of
74 treatment that was of insufficient potency to eliminate all infected cells²⁴. The model
75 suggested that this phenomenon could theoretically occur during early symptomatic
76 treatment as well. At the time, we downplayed the significance of model-generated
77 rebound as the phenomenon had yet to be demonstrated clinically. However, models fit
78 to rebound data now suggest a similar mechanism of action²⁵.

79 Here we use an updated model for SARS-CoV-2 viral kinetics that was first validated
80 against a much larger panel of untreated individuals to precisely simulate the virologic
81 outcomes of two nirmatrelvir/ritonavir trials. We identify that the true *in vivo* potency
82 of nirmatrelvir is significantly less than its *in vitro* potency, such that drug levels are
83 sub-therapeutic during a portion of the dosing interval. Viral rebound is observed in our
84 simulations and is more likely when the drug is dosed early during infection and is not
85 reduced with a higher dose or dosing frequency. Extended-duration treatment is
86 identified as the best strategy to avoid viral rebound.

87

88 **Results**

89 **Viral Dynamic, Pharmacokinetic, and Pharmacodynamic Mathematical models**

90 To derive parameters for simulating nasal viral loads in the absence of therapy, we used
91 the mechanistic mathematical model (**Fig 1a**) that best recapitulated 1510 SARS-CoV-
92 2 infections in a cohort of 1440 SARS-CoV-2 infected individuals from the National
93 Basketball Association cohort²⁶. The model assumes a finite number of susceptible
94 cells. An eclipse phase delays viral production by infected cells. In keeping with an
95 early interferon-mediated innate immune response, susceptible cells can become
96 refractory to infection in the presence of infected cells but also revert to a susceptible
97 state at a constant rate. Infected cells are cleared by cytolysis, a constant early immune
98 response rate, and delayed acquired immunity, which is activated in a time-dependent
99 fashion. We used a mixed-effect population approach implemented in Monolix to
100 estimate model parameters (**Fig S1, Table S1**).

101 To reproduce levels of nirmatrelvir, we used a two-compartment pharmacokinetic (PK)
102 model (Error! Reference source not found.**b**). Using Monolix and the mixed-effect
103 population approach, we estimated parameter values by fitting the model to the plasma
104 concentration of healthy subjects. The model closely recapitulated observed drug levels
105 following a single dose of 250mg/100mg of nirmatrelvir/ritonavir (**Fig S2, Table S2**).
106 The effect of ritonavir as a metabolic inhibitor is accounted for in nirmatrelvir's
107 clearance rate in the PK model. We also fit the model to population-level plasma
108 concentrations following a single dose of 250mg/100mg and 750mg/100mg, showing
109 that estimated parameters are dose-independent (**Table S3**).

110 For the pharmacodynamic (PD) model, we assumed drug efficacy follows a Hill
111 equation with respect to concentration. We parameterized the model using *in vitro*
112 efficacy data collected at different concentrations of nirmatrelvir (details in **Materials**
113 **and Methods, Fig S3, Table S4**).

114 Finally, we combined the viral dynamic and PKPD models by using treatment efficacy
115 to lower the viral production rate (details in **Materials and Methods, Fig 1**). We fit the
116 combined model to viral load drop from baseline reported in two randomized,
117 controlled trials: the EPIC-HR trial with 1574 high-risk unvaccinated symptomatic
118 individuals¹ (**Fig 2**) and the PLATCOV trial with 144 low-risk, symptomatic
119 individuals (**Fig 3a-e**)⁵. We also fit the combined model to individual viral load data
120 from PLATCOV (**Fig 3f-h, Fig S4 & Fig S5, Table S5**).

121 **Mathematical model fitting to clinical trial virologic outcome data**

122 The *in vivo* potency of a drug is often different from values measured *in vitro*^{23,28,29}. We
123 define the *in vivo* IC₅₀ as the plasma drug concentration required to inhibit viral
124 replication by 50% and the potency reduction factor (prf) as the ratio between the *in*

125 *vivo* and *in vitro* IC₅₀. To identify the *in vivo* potency of nirmatrelvir, we estimated the
126 prf using two methods.

127 For the first method, we simulated virtual cohorts using the combined viral dynamic-
128 PKPD model and fit the results to viral load decay from baseline in two trials. For each
129 trial arm, we randomly selected 400 individuals from the NBA cohort with the closest
130 matching viral variant, symptom, and vaccine status (unvaccinated symptomatic
131 subgroup for EPIC-HR and symptomatic Omicron infection for PLATCOV) and used
132 their estimated individual viral dynamic parameters in simulations. This approach
133 generated a wide, realistic range of shedding kinetic patterns among simulated
134 participants (**Fig S1**).

135 We next addressed variability in the timing of baseline viral load measurement relative
136 to infection. We randomly assigned all individuals an incubation period selected from a
137 variant-specific gamma distribution found in the literature.²⁷ Treatment start day was
138 randomly selected from a uniform distribution for each individual within 3 days of
139 symptom onset for EPIC-HR trial and within 4 days for the PLATCOV trial.

140 For all simulated individuals in the treatment arm, PK parameters were randomly
141 drawn from the estimated lognormal population parameter distributions (**Table S2**) and
142 PD parameters from a normal distribution with estimated mean and standard error
143 (**Table S4**). To estimate the prf, we simulated our virtual cohort treated with 300 mg of
144 nirmatrelvir twice per day for five days with a range of values and selected the prf that
145 generated the best agreement between the average change from baseline in the
146 treatment arm of each trial and each simulation.

147 Our simulations recapitulated the mean change in viral load from baseline to multiple
148 timepoints during the two weeks following study enrollment in EPIC-HR (Error!
149 Reference source not found.**a**) and PLATCOV (**Fig 3a**). Similarly, with optimized prf
150 estimates, the model closely recapitulated mean viral load reduction in the treatment
151 arms of both trials (**Figs 2b and 3b**).

152 Our model also predicted individual-level variability in virologic responses observed in
153 PLATCOV, including instances of increased viral load following therapy. We
154 compared simulated and actual distributions of viral load change among trial
155 participants in the control and treatment arms. On most post-treatment days, simulated
156 and actual distributions were not statistically dissimilar (**Fig 3d, e**). Wider distributions
157 of observed versus simulated viral load change were noted on post-randomization days
158 1 and 2 for control and days 1 and 4 for treatment (**Fig 3d, e**), perhaps due to noise in
159 viral load data from oral swabs: differences of 1-2 logs were often noted between
160 replicates collected from PLATCOV participants at equivalent timepoints, particularly
161 on day 1 and 2 (**Fig S6**).

162 **Reduction of *in vivo* nirmatrelvir potency relative to *in vitro***

163 We plotted the coefficient of determination, R², for fit to viral load data assuming
164 different prf values (**Figs 2c and 3c**). The best values (prf=61 for EPIC-HR and prf=37
165 for PLATCOV) were determined by maximizing the R² of the fit. We repeated the
166 simulation 10 times: the boxplot in the lower panel of **Figs 2c and 3c** represents the
167 standard error of the prf average value and does not reflect individual variability.

168 The reason for slight differences in estimated prfs between the two trials is unknown.
169 Possible explanations include different sampling methods (nasal swabs in EPIC-HR
170 versus oropharyngeal swabs in PLATCOV), different trial participant characteristics

171 (high-risk adults in EPIC-HR versus lower-risk adults without comorbidities in
172 PLATCOV), and differing dominant viral variants between the trials.

173 **Mathematical model fitting to individual viral load trajectories in PLATCOV**

174 For the second method, we fit the combined viral dynamic-PKPD model to individual
175 viral load data from the PLATCOV trial. Since samples were collected after
176 enrollment, we also included data from symptomatic Omicron-infected individuals in
177 the NBA cohort to inform the population model about viral expansion rates during
178 early infection. We used a mixed-effect population approach in Monolix to estimate
179 each participant's viral dynamic parameters and their potency reduction factor (prf)
180 (details in **Materials and Methods**). Our model closely recapitulated viral load
181 trajectories, including cases with post-treatment rebound (**Fig 3f-g**). The estimated
182 individual prf values were lognormally distributed, with a median of 39.79 (IQR 27.25-
183 55.75, range 13.51-105.03) (**Fig 3h, Table S5**).

184 The estimated population distribution of viral load parameters for Omicron-infected
185 individuals of the NBA cohort and the PLATCOV trial were the same except for ϕ (a
186 proxy for the innate immune response), τ (timing of the adaptive immune response),
187 and t_0 (infection time) (**Fig S7**). Time is measured relative to the day of detection in the
188 NBA cohort and relative to the day of baseline measurement in the PLATCOV trial, so
189 the larger t_0 and τ values for PLATCOV reflect the delay between infection and trial
190 enrollment. The reason for slight differences in estimated ϕ values between the two
191 groups is unknown but might be due to the different sampling methods (nasal swabs for
192 NBA versus oropharyngeal swabs for PLATCOV).

193 To further validate our model, we ran counterfactual simulations switching the
194 PLATCOV treatment and control arms (**Fig S8 c & d**). We treated participants in the
195 control arm of the trial (treatment counterfactual) and removed treatment from
196 participants in the treatment arm (control counterfactual). Due to treatment effect, onset
197 of the adaptive immune response was not easily identifiable for the treatment arm.
198 Therefore, when running the control counterfactual simulation, we assigned random
199 τ values from the estimated control arm distribution. Counterfactual simulations
200 reproduced the mean viral load drop from baseline observed in the trial (**Fig S8a & b**)
201 and predicted a diversity of responses to treatment. In some cases, treatment lowered
202 the peak and shortened infection (**Fig S8c(I) & d(III)**), while in other cases, treatment
203 had a more limited effect (**Fig S8c(IV) & d(II)**). Our results suggest that some
204 individuals with treatment-induced rebound may not have rebounded in their
205 counterfactual case (**Fig S8c(III)**), while some untreated individuals with persistent
206 infection might have experienced a treatment-induced rebound (**Fig S8d(I)**).

207

208 **Estimates of viral load reduction with an optimal drug**

209 To illustrate the importance of estimating *in vivo* drug potency, we compared the PKPD
210 projection and average change in viral load of treatment arms with prf=1 (no reduction
211 in potency) and prf=61 (as estimated in the EPIC-HR trial). With an approximately 61-
212 fold weaker potency, drug levels dropped below therapeutic level shortly after each
213 dose, due to its short half-life ($t_{1/2}$), and antiviral effect subsided within a day after
214 treatment ended maintaining an average efficacy of 82% (**eq. 3**) over the first 5 days of
215 treatment (**Fig 2d, e**). However, the plasma concentration of a perfectly potent drug
216 (prf=1) remained above therapeutic levels for the duration of treatment with a 5-day
217 average efficacy of 99.99% and the effect persisted for nearly 10 days (**Fig 2e**). If the *in*
218 *vivo* potency perfectly matched the measured *in vitro* potency (prf=1), the same

219 treatment regimen could reduce the viral load by approximately 3.5 logs at day 5
220 relative to the placebo compared to the 0.87 log reduction reported in the trial (**Fig 2f**).
221 While estimating nirmatrelvir's *in vitro* PD parameters, we assumed only the IC_{50}
222 differs *in vivo*. To confirm the validity of this assumption, we simulated the treatment
223 arm of EPIC-HR with different combinations of the prf and the Hill coefficient. **Fig S9**
224 shows that the best fit always happened for prf ~ 60 and was mostly independent of the
225 Hill coefficient.

226 The potency reduction factor was more sensitive to certain PK parameters (**Fig S10**),
227 particularly the drug's clearance rate (κ_{CL}). If the drug was cleared from the body more
228 rapidly-then it would need to be more potent to achieve the effect observed in the
229 clinical trial. However, this did not impact our alternate dosing regimen simulations
230 since PK parameters were independent of the dose (**Table S3**).

231 **Frequent viral rebound on nirmatrelvir**

232 To assess whether our model generated viral rebound, we assumed cohort
233 characteristics compatible with the PLATCOV trial (**Fig 3**) and randomly drew
234 individual prf values from the distribution obtained by fitting individual data (**Fig 3h**,
235 **Table S5**). We simulated from infection to 30 days after symptom onset, monitoring
236 viral load continually. We defined rebound in the control arm as any case with at least
237 two peaks in viral load with height greater than 3 logs and higher than its preceding
238 minimum by at least 1 log (**Fig S11a**). We defined rebound in the treatment arm as any
239 instance in which a post-treatment viral load exceeded the viral load at the end of the
240 treatment by 1 log (**Fig S11b**).

241 By this definition, we observed rebound in 18.15% of cases treated with the clinical
242 trial dose and 1.75% of controls in our simulations (**Fig 4b**). When a less sensitive
243 equivalent definition of rebound was used as in the trial (1 log increase in viral load 5
244 days after treatment cessation), the probability of rebound in the simulation was much
245 lower (4.12% if treatment was assumed to begin several days after symptoms), closer to
246 that of the controls, and comparable to that observed in the trial (**Fig S12**).

247 **Limited impact of nirmatrelvir dose or dosing frequency on viral rebound**

248 We next explored different treatment regimens to estimate their impact on lowering
249 viral load and the chance of rebound. We simulated therapy with 150, 300, 600, and
250 900 mg doses administered twice per day for 5 days, starting within 3 days post
251 symptom onset. Larger doses decreased viral load more significantly and quickly than
252 300 mg twice daily. 900 mg of nirmatrelvir reduced viral load by a mean of 2 logs on
253 day 2 and a mean of 4 logs on day 5 compared to the control (**Fig 4a**).

254 Individual viral loads were highly variable within each treatment group regardless of
255 dose (**Fig 4a**) due to heterogeneous underlying viral dynamics (**Fig S1**) and different
256 treatment timing. Responses to treatment also differed substantially according to viral
257 load trajectory and treatment timing (**Fig 4c**). The reduction in viral load was almost
258 always greater during the first 5 days of treatment with higher doses. However, this
259 only impacted viral elimination in certain cases (**Fig 4c,i**). Sometimes, viral load
260 equilibrated to similar levels post-treatment regardless of dose (**Fig 4c, ii**), while in
261 other cases, higher doses were associated with rebound (**Fig 4c, iv**). By achieving a
262 lower post-treatment viral load nadir, higher doses resulted in a greater likelihood of
263 viral rebound in our simulations (**Fig 4b**).

264 Increasing the frequency of antiviral dosing had nearly equivalent effects to increasing
265 the dose: a more rapid reduction in viral load (**Fig S13a**), heterogeneous effects based

266 on individual viral dynamics and treatment timing (**Fig S13c**), and increased chance of
267 rebound (**Fig S13b**).

268 **Early treatment as a predictor of SARS-CoV-2 rebound**

269 We next simulated therapy with four different treatment initiation windows: post-
270 exposure prophylaxis (PEP): 0-1 day after infection in the pre-symptomatic phase;
271 early treatment: 0-1 day after symptom onset as often occurs in community settings;
272 intermediate treatment: 1-5 days after symptom onset as in the clinical trial; and late
273 treatment: 5-10 days after symptom onset. In all simulations, the administered dosage
274 was 300mg twice per day for 5 days.

275 Applying treatment as PEP or shortly after symptoms lowered viral load more
276 substantially relative to control than intermediate or late therapy at days 2 and 5 post-
277 treatment, though intermediate and late strategies also significantly lowered viral load
278 relative to control at these time points (**Fig 5a**). However, PEP and early treatment were
279 associated with higher rebound probability after treatment (**Fig 5b, c**). The boxplots for
280 control groups in each panel in **Fig 5a** show the viral load at different points during
281 infection and are matched to different timing of nirmatrelvir in the treatment arms.

282 **Prolongation of treatment to reduce the probability of SARS-CoV-2 rebound**

283 Next, we analyzed the impact of treatment duration on viral rebound. We simulated
284 treatment regimens with 300mg nirmatrelvir twice per day for 2, 5, 10, 15, and 20 days.
285 Treatment was initiated within 3 days after symptoms appeared. **Fig 6a** demonstrates
286 the continuous drop in viral load if treatment was maintained until infection was
287 effectively cleared. The viral load distributions of the treatment arms with 15 and 20
288 days of treatment on days 2, 5, and 10 matched the viral load distribution of the
289 treatment arm with 10 days of treatment duration and, therefore, are not shown.
290 Prolonging treatment duration to 10 days almost eliminated viral rebound (**Fig 6b & c**).

291 We next explored the impact of treatment duration given different treatment initiation
292 time. Prolonging treatment to 15 days for early treatment and 20 days for PEP lowered
293 the viral load close to the limit of detection (1.26 log) at the end of treatment and
294 eliminated the probability of rebound for Omicron variants (**Fig 7**).

295 **Differing observed rebound rates resulting from varying timing of sampling and** 296 **definitions**

297 Previous studies defined rebound using criteria with varying virologic thresholds,
298 timing, and sampling frequency⁹. Rebound was sometimes defined when a positive test
299 followed a negative test³⁰. In EPIC-HR, treatment started within 5 days of symptoms
300 onset (our intermediate treatment group) and rebound was defined as a 0.5 log increase
301 on days 10 and/or 14. By this definition 2.3% of treated cases were classified as
302 rebound⁹. The probability of rebound in our simulation with a threshold of 0.5 log
303 measured only on day 5 after the end of the treatment was 5.45% and decreased as
304 thresholds for viral rebound increased (**Fig S12**). This percentage would be even lower
305 if treatment started 3-5 days after symptoms (rather than 1-5 days) because rebound
306 probability is very sensitive to treatment timing. We hypothesize that in EPIC-HR,
307 participant enrollments skewed later during the 5-day post-symptom window.

308 In our simulations, we recorded viral load every 0.001 of a day and used a 1 log
309 threshold to identify rebound cases. This was a more sensitive method to observe
310 rebound and suggests that in trial and real-world cohorts, rebound is likely more
311 common in treated individuals than is detected with less frequent sampling (**Fig S12**).

312

313 **Higher rebound probability in unvaccinated individuals with pre-Omicron variant** 314 **infection**

315 All simulations reported in **Figures 3-7** were performed assuming symptomatic,
316 vaccinated individuals with Omicron infection in the NBA cohort or PLATCOV. We
317 repeated simulations with characteristics compatible with the EPIC-HR trial
318 (unvaccinated symptomatic individuals with pre-Omicron variants) and prf values
319 randomly drawn from the distribution obtained in **Fig 2c**. The same patterns of rebound
320 probability were observed for altered treatment regimens. However, our model
321 predicted an overall higher rebound probability in unvaccinated individuals, infected by
322 pre-Omicron variants (**FigS14**). While 10 days of treatment would be sufficient to
323 lower the rebound probability significantly in the vaccinated individuals with Omicron
324 infection, 15 days of treatment would have been necessary to substantially lower the
325 incidence of rebound in unvaccinated individuals in the pre-omicron era.

326

327 **Immune and viral mechanisms for viral rebound**

328 To understand mechanisms that might explain higher rebound incidence in the PEP and
329 early treatment groups, we simulated four treatment arms with treatment starting on
330 days 1, 4, 7, and 10 after infection. Treatment start relative to infection was fixed to
331 limit the added variability introduced by incubation period and timing of treatment
332 relative to symptoms in previous simulations. High frequency of rebound with day 1
333 and day 4 treatment start was evident from viral load after treatment (**Fig 8a** top row) in
334 many individual trajectories (grey lines) and to a less dramatic extent in mean viral load
335 (blue line). A second peak after treatment ended was also seen in infected cells (**Fig 8a**
336 middle row, blue line) and the intensity of the innate immune response (the rate of
337 production of refractory cells) (**Fig 8a** bottom row).

338 Applying treatment earlier during infection (day 1 and 4 in our simulations) lowered
339 the viral load and the populations of infected and refractory cells, preserving
340 susceptible cells. In the earlier treatment groups the ratio of susceptible to refractory
341 cells was significantly higher at the end of the treatment than it was in the control group
342 at equivalent time points (**Fig 8b**). Innate immune responses were significantly
343 diminished in treated individuals versus controls due to fewer infected cells (**Fig 8c**).
344 Overall, a weaker innate immune response, higher availability of susceptible cells, and
345 persistence of infected cells after 5 days of treatment allowed viral rebound after
346 treatment cessation.

347 We previously partitioned the NBA cohort according to shedding kinetics using k-
348 means clustering²⁶. Groups were ordered by the area under their viral load curve
349 (AUC), with group 1 having the smallest AUC and group 6 the largest (**Fig S15a**). We
350 simulated treatment with different initiation days using these 6 groups and identified
351 the highest rebound probability in the earlier treatment groups when treating infections
352 that would have fast initial virus expansion (upslope) and high peak viral load (groups
353 2, 4, and 6) without treatment (**Fig S15b, c**).

354

355 **Discussion**

356 We previously demonstrated for HSV-2³¹, HIV³², Ebola virus²⁸, and SARS-CoV-2²³,
357 that considering the timing and intensity of the immune response is vital to accurately
358 simulate clinical trials of antiviral agents. If a direct-acting antiviral therapy is given too

359 late during infection, then efficacy is often low because the disease is driven by excess
360 inflammation and cytokine storm. On the other hand, concurrent immune pressure can
361 provide critical assistance for antiviral agents to eliminate viral replication, as
362 confirmed in recent studies⁷. Accordingly, previous modeling suggested that extremely
363 early treatment of pre-symptomatic SARS-CoV-2 as occurs with PEP requires higher
364 drug potency than treatment during early symptomatic infection because innate
365 immunity is more active at this slightly later stage of infection and fewer susceptible
366 cells remain²³. It is increasingly clear that the potency and duration of antiviral therapy
367 required to achieve clinical benefit depends strongly on the stage of infection and the
368 ongoing intensity of the immune response.

369 Prior work also demonstrated that *in vitro* antiviral drug potency measured in cell
370 culture often overestimates *in vivo* potency in humans^{28,29,33}. Specifically, the plasma
371 drug level required to achieve 50% inhibition of cellular infections *in vivo* is higher
372 than the level required *in vitro*. The discrepancy between *in vitro* and *in vivo* potency
373 can be assessed by fitting viral dynamic-PKPD mathematical models to viral load data
374 from clinical trials, as we have done here. Traditional PKPD models, which do not
375 include a dynamic immune response, are not sufficient to estimate *in vivo* potency.
376 Because *in vivo* potency reduction varies from 2 to 100 depending on the infection and
377 antiviral agents^{28,31,33}, population *in vivo* IC₅₀ must be assessed separately in each case.

378 Here, by precisely fitting a combined viral-immune dynamic / PKPD model to viral
379 load data from a randomized clinical trial as well as an open-label clinical trial of
380 nirmatrelvir/ritonavir, we merge these two key concepts. We first identify that
381 nirmatrelvir potency is reduced 60-70 fold *in vivo* relative to *in vitro* in the high-risk
382 population and 30-40 fold in the healthy population. The difference between the
383 estimated *in vivo* potency in these two populations might be explained by differences in
384 demographics, sampling methods, and the dominant viral variants in the two trials.
385 However, both values fall within the range of inter-individual variability estimated by
386 fitting the model to the individual viral loads of the second trial. The mechanistic
387 reasons for this reduction cannot be determined by the model, but may include
388 increased *in vivo* protein binding³⁴, inhibition of drug delivery from plasma to sites of
389 infection, or differences in cellular uptake and drug metabolism *in vivo*³⁵. Nevertheless,
390 our estimated *in vivo* IC₅₀ provides a benchmark plasma level to target in future trials.
391 The PKPD model also demonstrates that the drug's relatively short half-life allows it to
392 dip to subtherapeutic levels even when dosed twice daily.

393 Our model also develops a viable hypothesis for why nirmatrelvir is highly effective
394 when given during early symptomatic infection but less so when given as post-exposure
395 prophylaxis. By preventing a high peak viral load approximately 3-5 days after
396 infection, therapy preserves susceptible cells and blunts the immediate, likely innate
397 immune response to SARS-CoV-2, while not eliminating infected cells. If the virus is
398 not eliminated by an early acquired response along with antiviral pressure, it rebounds
399 to a peak level that is sometimes comparable to the initial peak. We hypothesize that
400 viral rebound occurs more frequently in community settings relative to the clinical trial,
401 because infected individuals in the community are often prescribed the drug very early
402 after symptom development, whereas in the trial, there was a natural 1 to 2-day delay
403 based on the enrollment and consent process. Surprisingly, this short delay may have
404 limited rebound while not affecting the primary endpoints of the trial, a finding
405 supported by recent clinical studies³⁰, which nevertheless still suggests a clear benefit
406 for earlier treatment in terms of preventing hospitalization in high-risk individuals⁷.
407 Notably, antiviral therapy is not a risk factor for rebound in our model or in clinical

408 cohorts if administered late during infection³⁶. However, high viral load shedding is a
409 risk factor for rebound in our model, as suggested in other studies³⁷.

410 Our model identifies optimal conditions for viral rebound, which, counterintuitively,
411 include early treatment during pre-symptomatic infection and higher or more frequent
412 dosing. Both factors suppress the amount of infection, thereby preserving susceptible
413 cells, limiting the development of refractory cells, and dampening the intensity of the
414 early immune response. The best method to prevent viral rebound is prolonging
415 treatment, with a longer course needed for PEP. This finding is consistent with trials of
416 long-acting monoclonal antibodies, which demonstrated efficacy as post-exposure
417 prophylaxis¹²⁻¹⁴.

418 Because our model is validated precisely against mean viral load reduction from two
419 trials as well as individual viral kinetics it can be used as a tool to test treatment
420 strategies varied therapeutic goals, timing of treatment, dose, dosing interval, and
421 duration of therapy. Our prior PD modeling also allows testing of potentially
422 synergistic agent combinations and consideration of special hosts such as
423 immunocompromised individuals with persistent infection who may be at risk of
424 developing drug resistance^{28,38,39}. We believe our approach provides a template for
425 optimizing future trial designs with nirmatrelvir and other therapies.

426 Our model has several limitations. First, nasal or oropharyngeal viral load is not a
427 perfect surrogate of disease activity. On the one hand, viral load reduction has been
428 correlated with beneficial clinical outcomes for nirmatrelvir¹, molnupiravir⁴⁰, and
429 monoclonal antibodies⁴¹. A recent review shows that viral load reduction is a
430 reasonably good surrogate endpoint⁴¹. Moreover, viral rebound appears to track very
431 closely with symptomatic rebound in multiple case series⁹. Yet, early remdesivir
432 treatment provided a profound reduction in hospitalization while not impacting nasal
433 viral load, albeit 5 days after completion of therapy⁴². Data from non-human primates
434 suggests that the drug has a specific effect on viral loads in the lungs that is not
435 observed in upper airways, a finding that we were also²³. Overall, there is a strong
436 suggestion from early treatment trials that a reduction in nasal viral loads beyond that
437 observed in placebo-treated individuals is associated with substantial clinical benefit¹.

438 Another limitation is that the model does not account for drug resistance. While there
439 has been limited evidence of de novo resistance during nirmatrelvir therapy, serial
440 passage of virus suggests a relatively low barrier, and some viral rebound could, in
441 theory, be with resistant variants. Studies to date suggest very little mutational change
442 between the infecting and rebounding virus⁴³⁻⁴⁶.

443 Our model does not capture immunity in literal terms. For instance, we do not
444 distinguish innate interferon, antibody, and T-cell responses, as these have not been
445 measured in sufficient longitudinal detail to precisely ascribe viral clearance to different
446 components of the immune response. We structured the model for the early response to
447 roughly map to innate responses, as the model term capturing the progression of
448 susceptible cells to a refractory state diminishes with decreases in viral load and
449 assumes no immune memory. The late immune response in our model has memory,
450 leads to rapid elimination of the virus, and is likely to represent acquired immunity.
451 While a more accurate model would discriminate different arms of the immune
452 responses and fit to immune data, ours sufficiently captures the timing and intensity of
453 immune responses for accurate clinical trial simulation.

454 Finally, it is our opinion that models lacking a spatial component cannot fully describe
455 target cell limitation, which is influenced by the packing structure of cells, viral

456 diffusion, and infection within multiple concurrent micro-environments³¹.
457 Consequently, ordinary differential equations may misclassify the relative impact of
458 target cell limitation and innate immune responses in the period surrounding peak viral
459 load. However, our approach provides accurate output for clinical trial simulation.

460 In conclusion, our model identifies viable mechanistic underpinnings of the high
461 efficacy of nirmatrelvir therapy for early symptomatic SARS-CoV-2 infection, lower
462 efficacy for PEP, and high incidence of viral rebound in a real-world setting. The model
463 can also be used to assess different treatment strategies and suggests prolonging therapy
464 is the optimal method to avoid rebound while maintaining potent early antiviral
465 suppression.
466

467 **Materials and Methods**

468 **Study Design**

469 We developed a viral dynamics model recapitulating viral load data collected from
470 symptomatic individuals in the NBA (National Basketball Association) cohort⁴⁷. We
471 used a two-compartment model to reproduce the PK data of nirmatrelvir plus ritonavir².
472 For clinical trial simulation, we constructed a virtual cohort by randomly selecting 400
473 individuals from the NBA cohort, trying to match the trial populations regarding
474 vaccine status and history of infection, and assigning individual PK and PD parameters
475 randomly drawn from their respective inferred distributions. We fit the combined viral
476 dynamic and PKPD model to the average change in viral load from the baseline as well
477 as individual viral load data of the control and treatment arms of two previously
478 published nirmatrelvir/ritonavir clinical trials^{1,5}. Comparing our model to the control
479 arms validated our viral dynamic model and demonstrated how well our virtual cohorts
480 represent the trial control arms. As one method of fitting the treatment arms, we used
481 the average data from the treatment arms to estimate the potency reduction factor (prf)
482 by maximizing the R^2 of the fit. In a second approach, we fit to individual viral load
483 trajectories in PLATCOV using the mixed-effect population approach implemented in
484 Monolix and obtained both individual prf values and a population distribution. With the
485 estimated prf and *in vivo* IC_{50} of the drug, we explored different treatment regimens by
486 changing dose, dosing frequency, treatment duration, and treatment timing to find the
487 best strategy to minimize the probability of rebound.

488 **Viral load data**

489 The NBA cohort dataset published by Hay et al⁴⁷ consists of 2875 documented SARS-
490 CoV-2 infections in 2678 people detected through frequent PCR testing regardless of
491 symptoms. We used the viral load data from 1510 infections in 1440 individuals that
492 had at least 4 positive quantitative samples to estimate viral dynamic parameters. We
493 used parameter sets estimated for the symptomatic subpopulation of these individuals
494 to construct virtual cohorts.

495 **Clinical trial data**

496 We used viral load data from two nirmatrelvir/ritonavir clinical trials. EPIC-HR by
497 Hammond et al.¹ included 682 and 697 symptomatic high-risk individuals in the control
498 and treatment arms, respectively. We obtained the average change in viral load data of
499 the control and treatment arms by digitizing Figure 3A of the manuscript by Hammond
500 et al.¹. Nasal viral load was measured using PCR assay on days 0, 3, 5, 10, and 14 after
501 the treatment start day and adjusted by the baseline viral load. PLATCOV by Schilling
502 et al.⁵ is an open-label, randomized, controlled adaptive trial with 85 and 59

503 symptomatic, young, healthy individuals in the control and nirmatrelvir treatment arms,
504 respectively. The oropharyngeal samples from each participant were collected daily on
505 days 0 through 7 and on day 14 after the treatment start day, and viral load was
506 measured using PCR assay. We used the individual viral load data published by the
507 authors. From PLATCOV, we averaged over the two oral samples collected from each
508 individual and calculated viral load drop from baseline (to use in method 1, Figure 3) or
509 used the individual-level viral load data (in method 2, Figure 3). In both trials, the study
510 participants were treated with 300mg/100mg nirmatrelvir/ritonavir within three days
511 (EPIC-HR) or four days (PLATCOV) of symptom onset. The treatment was
512 administered twice per day, for five days. We used EPIC-HR's lower limit of detection
513 (LOD = 2 logs imputed as 1 log) in the simulations where we used EPIC-HR cohort
514 characteristics (unvaccinated symptomatic individuals) (Figures S9, S10, and S14).
515 When fitting to PLATCOV cohort characteristics (vaccinated symptomatic individuals
516 with omicron infection) and in all the simulations in the main paper, we used the
517 maximum LOD reported in the published data (~1.26 log).

518 **PK data**

519 PK data of nirmatrelvir (PF-07321332) with ritonavir was obtained by digitizing Figure
520 4 of the drug's Emergency Use Authorization document² using WebPlotDigitizer⁴⁸.
521 The data is from a phase I randomized trial by Singh et al.⁴⁹ where eight participants (4
522 fed, 4 fasting) took a single dose of 250mg/100mg nirmatrelvir/ritonavir. Drug
523 concentrations in plasma were recorded for 48 hours following dosing.

524 **PD data**

525 The data on drug efficacy experiments performed at the University of Washington. The
526 efficacy of nirmatrelvir in the presence of CP-100356 (an efflux inhibitor⁵⁰) was
527 measured against the delta variant of SARS-CoV2 in Calu-3 cells (human lung
528 epithelial). The efflux inhibitor ensures consistent, adequate intracellular levels of drug.
529 Briefly, Calu 3 cells were treated with varying concentrations of nirmatrelvir in the
530 presence of 2uM CP-100356 prior to infection with SARS-CoV-2 (delta isolate) at a
531 multiplicity of infection of 0.01. Antiviral efficacy and cell viability (of non-infected
532 cells treated with drugs) were assessed as described⁵¹. There were five replicates per
533 condition, pooled from 2 independent technical experimental repeats (one experiment
534 with triplicate conditions, one experiment in duplicate conditions).

535 **Viral dynamics model**

536 We used our model of SARS-CoV-2 dynamics²⁶ to model the viral load of
537 symptomatic individuals with SARS-CoV-2 infection. Our model assumes that
538 susceptible cells (S) are infected at rate βVS by SARS-CoV-2 virions. The infected
539 cells go through a non-productive eclipse phase (I_E) before producing viruses and
540 transition to becoming productively infected (I_P) at rate κI_E . When encountering
541 productively infected cells, the susceptible cells become refractory to infection (R) at
542 the rate $\phi I_P S$. Refractory cells revert to a susceptible state at rate ρR . The productively
543 infected cells produce virus at the rate πI_P and are cleared at rate δI representing
544 cytolysis and the innate immune response that lacks memory and is proportional to the
545 amount of ongoing infection. If the infection persists longer than time τ , then cytotoxic
546 acquired immunity is activated, which is represented in our model by the rate $m I_P$.
547 Finally, free virions are cleared at the rate γ . Of note, this model, previously proposed
548 by Ke et al.⁵², was selected against other models in²⁶ based on superior fit to data and
549 parsimony. The model written as a set of differential equations has the form,

550

$$551 \quad \frac{dS}{dt} = -\beta SV - \phi I_P S + \rho R \quad (1a)$$

$$552 \quad \frac{dR}{dt} = \phi I_P S - \rho R \quad (1b)$$

$$553 \quad \frac{dI_E}{dt} = \beta SV - \kappa I_E \quad (1c)$$

$$554 \quad \frac{dI_P}{dt} = \kappa I_E - \delta I_P - m(t)I_P \quad (1d)$$

$$555 \quad \frac{dV}{dt} = \pi I_P - \gamma V \quad (1e)$$

$$556 \quad \text{where } \begin{cases} m(t) = 0 & t < \tau \\ m(t) = m & t \geq \tau \end{cases} \quad (1f)$$

557

558 To estimate parameter values, we fit the model to viral load data from the NBA cohort
 559 using a mixed-effect population approach implemented in Monolix. Details on the
 560 model selection and fitting process can be found in Owens et al²⁶. Information about
 561 parameter distributions and the error model is provided in **Table S1**.

562 We start the simulations with 10^7 susceptible cells. The initial value of the refractory
 563 cells is assumed to be zero since the interferon signaling is not active prior to infection.
 564 We further assume there are no infected cells (eclipse or productive) at the beginning of
 565 the infection. We fix the level of inoculum (V_0) at 97 copies/ml for each individual.

566 To resolve identifiability issues, we fixed two parameter values, setting the inverse of
 567 the eclipse phase duration to $\kappa = 4$, and the rate of clearance of virions to $\gamma = 15$ ²⁶.

568 **PK model**

569 We used a two-compartmental PK model which includes the amount of drug in the GI
 570 tract (A_{GI}), the plasma compartment (A_P), and the lung (A_L). The drug is administered
 571 orally, passes through the GI tract and gets absorbed into the blood at the rate κ_a . The
 572 drug then transfers from the blood into the peripheral compartment (or the lung) at the
 573 rate κ_{PL} . The metabolized drug transfers back into the plasma at the rate κ_{LP} from
 574 where it clears from the body at the rate κ_{CL} . The model in the form of ordinary
 575 differential equations is written as,

$$576 \quad \frac{dA_{GI}}{dt} = -\kappa_a A_{GI} \quad (2a)$$

$$577 \quad \frac{dA_P}{dt} = \kappa_a A_{GI} + \kappa_{LP} A_L - (\kappa_{CL} + \kappa_{PL}) A_P \quad (2b)$$

$$578 \quad \frac{dA_L}{dt} = \kappa_{PL} A_P - \kappa_{LP} A_L \quad (2c)$$

579

580 We used Monolix and a mixed-effect population approach to estimate the parameters
 581 and their standard deviations. With the initial condition of ($A_{GI} = Dose$, $A_P = 0$, $A_L =$
 582 0); we fit $C_P = \frac{A_P}{Vol}$ to the plasma concentration data where Vol is the estimated plasma
 583 volume. Details on parameter distributions and the error model provided in **Table S2**.

584

585 **PD model**

586 For the pharmacodynamics model we used Hill equation, $\epsilon(t) = \frac{E_{max}C(t)^n}{C(t)^n + IC_{50}^n}$, where $C(t)$
587 is the drug's concentration in plasma, E_{max} is the maximum efficacy, n is the Hill
588 coefficient, and IC_{50} is the drug concentration in plasma required for 50% efficacy. We
589 used least-squared fitting to obtain the three parameters (E_{max} , n , and IC_{50}) and their
590 standard deviations. The average drug efficacy is measured using,

$$591 \quad E_{ave} = \frac{1}{t_{start} - t_{end}} \int_{t_{start}}^{t_{end}} \epsilon(t) dt \quad (3)$$

592 Where t_{start} and t_{end} are the treatment start day and end day, respectively.

593

594 Combined PKPD and VL models

595 The plasma concentration of nirmatrelvir obtained from the PK model is used in the PD
596 model to obtain time-dependent efficacy. $\epsilon(t)$, then, is used to reduce viral production
597 rate, π , with the factor of $(1 - \epsilon(t))$. Equation 1e is written as,

$$598 \quad \frac{dV}{dt} = (1 - \epsilon(t))\pi I_P - \gamma V \quad (4)$$

599 Fitting the combined model to individual viral load data in the PLATCOV trial

600 We used the population mixed-effect approach and Monolix to estimate each
601 individual's viral dynamics parameters and the potency reduction factor (prf). Due to
602 the lack of data from the initial phase of infection in the PLATCOV trial, we include
603 the data from Omicron-infected individuals in the NBA cohort to inform the model
604 about the initial phase of infection. We fixed the PK parameters to the estimated
605 population values (**Table S2**), and the PD parameters other than IC_{50} to the *in vitro*
606 estimated population values (**Table S4**). We used the study category (NBA vs
607 PLATCOV) as a covariate for t_0 (timing of infection) and τ (timing of the adaptive
608 immune response) since the first recorded positive test is likely much later for the
609 clinical trials. In the NBA study, samples were collected almost daily regardless of
610 symptoms often leading to pre-symptomatic detection, while in the PLATCOV study,
611 the baseline measurement occurred after symptom onset, trial enrollment and consent.

612 Construction of a virtual cohort

613 To generate a cohort for our simulated clinical trials, we randomly selected 400
614 individuals (for each arm of the simulated trials) from the unvaccinated symptomatic
615 subpopulation of the NBA cohort for EPIC-HR and vaccinated with Omicron infection
616 for PLATCOV and used their individual viral load parameters estimated by fitting our
617 viral dynamics model to the data. A sample size of $n=400$ (out of 822 vaccinated
618 individuals with Omicron infection) was used to mimic a large-scale clinical trial and
619 maintain relatively low overlap between virtual cohorts used in each arm of the
620 simulations and between different simulations. Since the time of symptom onset is not
621 available for all individuals in the NBA data, we randomly drew an incubation period
622 for each individual from gamma distributions with variant-specific parameters
623 estimated by Gamiche et al.²⁷ The start of treatment relative to symptom onset was
624 randomly selected according to a uniform distribution, except when constructing **Fig. 8**.
625 The PK parameters of each simulated individual were randomly drawn from lognormal
626 distributions, for which estimated mean and standard deviation were inferred from the
627 PK data. The relevant dose in each scenario was added to the A_{GI} compartment (the
628 absorption equation) of the PK model (**eq 2a**) at each dosing timepoint ($t=0, 0.5, 1, 1.5,$
629 $\dots, 4.5$ days). For all doses, we used the PK parameter distributions estimated for 250

630 mg since our analysis showed they are dose-independent. PD parameters were also
631 randomly drawn from a normal distribution with the estimated mean and standard
632 deviation. The standard deviation of the PD parameters represents the accuracy of the
633 assays and not individual variability. The individual potency reduction factors were
634 also drawn from a lognormal distribution with estimated mean and standard deviation
635 obtained from fitting the model to the individual viral load data of PLATCOV study.

636 Potency reduction factor (prf)

637 The prf is defined as,

$$638 \text{ prf} = \frac{IC_{50,in vivo}}{IC_{50,in vitro}} \quad (5)$$

639

640 We estimated the prf by maximizing R^2 when fitting the change in viral load of the
641 treatment arm of our simulation to the data from the treatment arm of the clinical trial.

642 Measuring rebound probability

643 A viral load rebound in the treatment arm was defined when the viral load at any time
644 after treatment ended exceeded the viral load at the end of the treatment by 1 log. In the
645 control group, viral rebound was defined in patients who had at least two peaks with
646 maximum height of 1000 copies/ml in their viral load trajectories and the second peak
647 was 1 log higher than its preceding local minimum (**Fig S7**).

648

649

650 References

651

652 Hammond, J. *et al.* Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. *N Engl J Med* **386**,
653 1397–1408 (2022).

654 Emergency Use Authorization for Paxlovid (nirmatrelvir tablets co-packaged with ritonavir tablets) Center for
655 Drug Evaluation and Research (CDER) Review. *Food and Drug Administration* (2021).

656 Khunte, M., Kumar, S., Salomon, J. A. & Bilinski, A. Projected COVID-19 mortality reduction from paxlovid
657 rollout. *JAMA Health Forum* **4**, E230046 (2023).

658 FDA approves first oral antiviral for treatment of COVID-19 in adults. *Food and Drug Administration*

659 [https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-](https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults)
660 [adults](https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults).

661 Schilling, W. H. K. *et al.* Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with
662 early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. *Lancet*
663 *Infect Dis* **24**, 35–45 (2023).

664 Pandit, J. A. *et al.* The Coronavirus disease 2019 rebound study: a prospective cohort study to evaluate viral and
665 symptom rebound differences in participants treated with nirmatrelvir plus ritonavir versus untreated controls.
666 *Clinical Infectious Diseases* **77**, 25–31 (2023).

667 Wong, C. K. H. *et al.* Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or
668 diagnosis: target trial emulation. *Nat Commun* **14**, (2023).

669 Wang, L. *et al.* COVID-19 rebound after Paxlovid and Molnupiravir during January–June 2022. *medRxiv* (2022)
670 doi:10.1101/2022.06.21.22276724.

671 Anderson, A. S., Caubel, P. & Rusnak, J. M. Nirmatrelvir–ritonavir and viral load rebound in Covid-19. *N Engl J*
672 *Med* **387**, 1047–1049 (2022).

673 Pfizer shares top-line results from phase 2/3 EPIC-PEP study of PAXLOVID™ for post-exposure prophylactic
674 use. *Pfizer* [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study)
675 [23-epic-pep-study](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-top-line-results-phase-23-epic-pep-study).

676 Merck provides update on phase 3 MOVE-AHEAD trial evaluating LAGEVRIO™ (molnupiravir) for post-
677 exposure prophylaxis for prevention of COVID-19 - Merck.com. [https://www.merck.com/news/merck-provides-](https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/)
678 [update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-](https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/)
679 [prevention-of-covid-19/](https://www.merck.com/news/merck-provides-update-on-phase-3-move-ahead-trial-evaluating-lagevrio-molnupiravir-for-post-exposure-prophylaxis-for-prevention-of-covid-19/).

- 680 Hirsch, C. *et al.* SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. *Cochrane Database*
681 *Syst Rev* Art. No.: CD014945 (2022) doi:10.1002/14651858.CD014945.PUB2.
- 682 O'Brien, M. P. *et al.* Effect of subcutaneous Casirivimab and Imdevimab antibody combination vs placebo on
683 development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical
684 trial. *JAMA* **327**, 432–441 (2022).
- 685 O'Brien, M. P. *et al.* Subcutaneous REGEN-COV antibody combination to prevent Covid-19. *N Engl J Med* **385**,
686 1184–1195 (2021).
- 687 Herman, G. A. *et al.* Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of
688 COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial. *Lancet Infect Dis* **22**,
689 1444–1454 (2022).
- 690 Su, K. *et al.* A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV
691 dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. *PLoS Biol* **19**, e3001128 (2021).
- 692 Wang, S. *et al.* Modeling the viral dynamics of SARS-CoV-2 infection. *Math Biosci* **328**, 108438 (2020).
- 693 Perelson, A. S. & Ke, R. Mechanistic modeling of SARS-CoV-2 and other infectious diseases and the effects of
694 therapeutics. *Clin Pharmacol Ther* **109**, 829–840 (2021).
- 695 Sanche, S. *et al.* A simple model of COVID-19 explains disease severity and the effect of treatments. *Sci Rep* **12**,
696 14210 (2022).
- 697 Czuppon, P. *et al.* Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and
698 impact of different drug-specific mechanisms of action. *PLoS Comput Biol* **17**, e1008752 (2021).
- 699 Gonçalves, A. *et al.* Timing of antiviral treatment initiation is critical to reduce SARS-CoV-2 viral load. *CPT*
700 *Pharmacometrics Syst Pharmacol* **9**, 509–514 (2020).
- 701 Iwanami, S. *et al.* Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in
702 randomized controlled trials: A modeling study. *PLoS Med* **18**, 25 (2021).
- 703 Goyal, A., Cardozo-Ojeda, E. F. & Schiffer, J. T. Potency and timing of antiviral therapy as determinants of
704 duration of SARS-CoV-2 shedding and intensity of inflammatory response. *Sci Adv* **6**, (2020).
- 705 Fumagalli, V. *et al.* Nirmatrelvir treatment of SARS-CoV-2-infected mice blunts antiviral adaptive immune
706 responses. *EMBO Mol Med* **15**, e17580 (2023).
- 707 Perelson, A. S., Ribeiro, R. M. & Phan, T. An explanation for SARS-CoV-2 rebound after Paxlovid treatment.
708 *medRxiv* (2023) doi:10.1101/2023.05.30.23290747.
- 709 Owens, K., Esmacili, S. & Schiffer, J. T. Heterogeneous SARS-CoV-2 kinetics due to variable timing and
710 intensity of immune responses. *JCI Insight* (2024) doi:10.1172/JCI.INSIGHT.176286.
- 711 Galmiche, S. *et al.* SARS-CoV-2 incubation period across variants of concern, individual factors, and
712 circumstances of infection in France: a case series analysis from the ComCor study. *Lancet Microbe* **4**, E409–
713 E417 (2023).
- 714 Finch, C. L. *et al.* Formulation, stability, pharmacokinetic, and modeling studies for tests of synergistic
715 combinations of orally available approved drugs against Ebola virus in vivo. *Microorganisms* **9**, 566 (2021).
- 716 Mayer, B. T. *et al.* Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.
717 *PLoS Comput Biol* **18**, (2022).
- 718 Edelstein, G. E. *et al.* SARS-CoV-2 virologic rebound with nirmatrelvir-ritonavir therapy. *medRxiv*
719 2023.06.23.23288598 (2023) doi:10.1101/2023.06.23.23288598.
- 720 Schiffer, J. T., Swan, D. A., Corey, L. & Wald, A. Rapid viral expansion and short drug half-life explain the
721 incomplete effectiveness of current herpes simplex virus 2-directed antiviral agents. *Antimicrob Agents*
722 *Chemother* **57**, 5820–5829 (2013).
- 723 Reeves, D. B. *et al.* Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated
724 Prevention (AMP) trials. *PLoS Comput Biol* **16**, (2020).
- 725 Schiffer, J. T. *et al.* Mathematical modeling of herpes simplex virus-2 suppression with pritelivir predicts trial
726 outcomes. *Sci Transl Med* **8**, (2016).
- 727 Greenfield, S. R. *et al.* Species differences in plasma protein binding of the severe acute respiratory syndrome
728 coronavirus 2 (SARS-CoV-2) main protease inhibitor nirmatrelvir. *Xenobiotica* **53**, 12–24 (2023).
- 729 Hau, R. K., Wright, S. H. & Cherrington, N. J. PF-07321332 (Nirmatrelvir) does not interact with human ENT1 or
730 ENT2: Implications for COVID-19 patients. *Clin Transl Sci* **15**, 1599–1605 (2022).
- 731 Wong, C. K. H. *et al.* Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in
732 Hong Kong: a population-wide retrospective cohort study. *Lancet Infect Dis* **23**, 683–695 (2023).
- 733 Pandit, J. A. *et al.* The Coronavirus Disease 2019 Rebound Study: A Prospective Cohort Study to Evaluate Viral
734 and Symptom Rebound Differences in Participants Treated With Nirmatrelvir Plus Ritonavir Versus Untreated
735 Controls. *Clin Infect Dis* **77**, (2023).
- 736 Zuckerman, N. S., Bucris, E., Keidar-Friedman, D., Amsalem, M. & Brosh-Nissimov, T. Nirmatrelvir
737 Resistance—de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged
738 Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure—a Case Report.
739 *Clinical Infectious Diseases* **ciad494**, (2023).

- 740 Xu, S. *et al.* Two-way pharmacodynamic modeling of drug combinations and its application to pairs of
741 repurposed Ebola and SARS-CoV-2 agents. *Antimicrob Agents Chemother* (2024) doi:10.1128/AAC.01015-
742 23/FORMAT/EPUB.
- 743 Jayk Bernal, A. *et al.* Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. *N Engl J Med* **386**,
744 509–520 (2022).
- 745 Elias, K. M. *et al.* Viral clearance as a surrogate of clinical efficacy for COVID-19 therapies in outpatients: A
746 systematic review and meta-analysis. *medRxiv* 2023.06.18.23291566 (2023) doi:10.1101/2023.06.18.23291566.
- 747 Gottlieb, R. L. *et al.* Early Remdesivir to prevent progression to severe Covid-19 in outpatients. *N Engl J Med*
748 **386**, 305–315 (2022).
- 749 Carlin, A. F. *et al.* Virologic and immunologic characterization of Coronavirus disease 2019 recrudescence after
750 Nirmatrelvir/Ritonavir treatment. *Clin Infect Dis* **76**, E530–E532 (2023).
- 751 Epling, B. P. *et al.* Clinical, virologic, and immunologic evaluation of symptomatic Coronavirus disease 2019
752 rebound following Nirmatrelvir/Ritonavir treatment. *Clin Infect Dis* **76**, 573–581 (2023).
- 753 Boucau, J. *et al.* Characterization of virologic rebound following Nirmatrelvir-Ritonavir treatment for
754 Coronavirus disease 2019 (COVID-19). *Clin Infect Dis* **76**, E526–E529 (2023).
- 755 Lai, C. C. & Hsueh, P. R. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment. *J Med*
756 *Viro* **95**, (2023).
- 757 Hay, J. A. *et al.* Quantifying the impact of immune history and variant on SARS-CoV-2 viral kinetics and
758 infection rebound: A retrospective cohort study. *Elife* **11**, (2022).
- 759 Rohatgi, A. WebPlotDigitizer. vol. 4.7 Software at <https://automeris.io/WebPlotDigitizer.html> (2024).
- 760 Singh, R. S. P. *et al.* Innovative randomized phase I study and dosing regimen selection to accelerate and inform
761 pivotal COVID-19 trial of Nirmatrelvir. *Clin Pharmacol Ther* **112**, 101–111 (2022).
- 762 Owen, D. R. *et al.* An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19.
763 *Science* **374**, 1586–1593 (2021).
- 764 Wagoner, J. *et al.* Combinations of host- and virus-targeting antiviral drugs confer synergistic suppression of
765 SARS-CoV-2. *Microbiol Spectr* **10**, (2022).
- 766 Ke, R. *et al.* Daily longitudinal sampling of SARS-CoV-2 infection reveals substantial heterogeneity in
767 infectiousness HHS Public Access. doi:10.5281/zenodo.6311388.
- 768
- 769
- 770

771 Acknowledgments

772

773 Funding:

774 National Institutes of Health (NIH) grants R01AI169427 (JTS)

775 National Institutes of Health (NIH) grants R01AI121129 (JTS)

776 National Institutes of Health (NIH) grants R01AI177512 (JTS, SJP)

777

778 Author contributions:

779 Conceptualization: JTS, SE, KO

780 Methodology: JTS, SE, KO

781 Software: SE, KO

782 Investigation: SJP, JW, SE, KO

783 Formal analysis: SE, KO

784 Writing – original draft: JTS, SE

785 Writing – review & editing: JTS, SE, KO, SJP, JW, JMW

786

787 Competing interests:

788 Authors declare that they have no competing interests.

789

790 Data availability:

791 The data analyzed in this work was previously published by Hay et al. and Schilling et
792 al. and is available on github at

793 <https://github.com/gradlab/SC2-kinetics-immune-history> and
794 <https://github.com/jwatowatson/PLATCOV-Molnupiravir/tree/V1.0>

795 Pharmacodynamics data is available on github at
796 https://github.com/sEsmaili/Covid_Rebound

797

798 **Code availability:**


799 All codes and materials used in the analysis is available on github at
800 https://github.com/sEsmaili/Covid_Rebound

801

802

803

804 **Figures and Tables**
 805
 806



807
 808 **Fig. 1. Schematics of the viral dynamic model and nirmatrelvir PK-PD two**
 809 **compartmental model.** (a) The viral dynamic model follows the dynamics of
 810 susceptible cells (S), refractory cells (R), eclipse infected cells (I_E), productively
 811 infected cells (I_P), and virus (V) and includes the early and late cytolytic T-cell immune
 812 responses with rates δ and m(t). β is the infection rate, φ is the rate of conversion of
 813 susceptible cells to refractory cells, and ρ is the rate of reversion of refractory cells to
 814 susceptible cells. Infected cells produce viruses at the rate π, and the free viruses are
 815 cleared at the rate γ. (b) Two-compartmental PK model with oral administration of the
 816 drug which models the amounts of the drug in gut tissue (A_{GI}), plasma (A_P), and the
 817 tissue (A_L). K_a is the rate of absorption of the drug from gut to plasma. K_{PL} and K_{LP} are
 818 the rates of transfer of the drug from plasma to the tissue and back, and K_{CL} is the rate
 819 at which the drug clears from the body. Vol is the estimated plasma volume and C_P is
 820 the drug concentration in plasma. ε(C_P) is the drug efficacy that blocks viral production
 821 and is calculated using the Hill equation: $\frac{E_{max}C_P^n}{C_P^n + (prf * IC_{50})^n}$ where E_{max} is the maximum
 822 efficacy, n is the Hill coefficient, IC₅₀ is the concentration of drug *in vitro* at which
 823 viral replication rate is reduced by 50%, prf is the potency reduction factor translating
 824 the *in vitro* potency to *in vivo* potency.
 825





Fig. 2. Lower *in vivo* potency of nirmatrelvir relative to *in vitro* potency in EPIC-HR. (a-b) mean (blue), individual (gray), and ranges (labeled dashed lines) of \log_{10} viral load drop from the baseline of individuals randomly selected from the NBA cohort treated with (a) placebo or (b) five days of nirmatrelvir / ritonavir 300 mg twice daily. The red dots were obtained by digitizing Fig 3a of Hammond et al.¹ and model fit was noted by closeness of blue lines to the red dots. (c) R^2 of the fit of the 10 model simulations per prf to the viral load drop data in light blue and their mean in dark blue. The best model fit was at a potency reduction factor of 61. The horizontal boxplot in the lower panel shows the distribution of prf values at which R^2 is maximum (mean = 61.8, median = 61, sd=3.5). (d) Drug efficacy when prf=61. Average efficacy was 82% over the 5-day interval, with notable drops in antiviral efficacy at drug troughs. (e) Projected average drug efficacy when prf = 1 vs prf = 61. The drug with no potency reduction has nearly perfect efficacy (average efficacy of 99.99%) over 5 days and has a prolonged post-treatment effect. (f) Projected mean \log_{10} viral load drop from baseline of the control arm, treatment arm with prf=61, and treatment arm with prf=1.

826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845

846



847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862

863

864

865

866


867

868

869

Fig. 3. Lower *in vivo* potency of nirmatrelvir relative to *in vitro* potency in PLATCOV. Method I: (a-b) mean (blue), individual (gray), and ranges (labeled dashed lines) of log₁₀ viral load drop from the baseline of individuals randomly selected from the NBA cohort treated with (a) placebo or (b) five days of nirmatrelvir / ritonavir 300 mg twice daily. The empty and filled red circles are individual and mean viral load drop from baseline calculated from viral load data published by Schilling et al.⁵. Model fit was noted by closeness of blue lines to the filled red dots. (c) R² of the fit of the 10 model simulations per prf to the viral load drop data in light blue and their mean in dark blue. The best model fit was at a potency reduction factor of 37. The horizontal boxplot in the lower panel shows the distribution of prf values at which R² is maximum (mean = 36.6, median = 37, sd = 2.15). (d-e) distribution of log₁₀ viral load drop from baseline of simulated cohort and the 144 individuals in PLATCOV control arm (d) and treatment arm (e). Adjusted p-values (q-values) were calculated using Benjamini-Hochberg method and represent dissimilarity between observed and simulated distributions. **Method II: (f-g)** sample individual fits to PLATCOV trial participants in control (f) and treatment (g) arms. (h) distribution of estimated individual prf values (center line, median; box limits, upper and lower quartiles; whiskers, 1.5x interquartile range, blue dots are the prf values for each individual in the treatment arm). Remaining fits are in Figs S4 and S5.


870
871
872



873
874
875
876
877
878
879
880
881
882
883
884
885
886
887


Fig. 4. Increasing the nirmatrelvir dose lowers short-term viral load but increases the probability of viral rebound. In all scenarios, simulated treatment starts within the first 3 days post-symptoms. **(a)** log₁₀ viral load at days 2, 5, and 10 after the treatment start day with different doses. p-values were obtained by performing two-sided Mann-Whitney U-test between the 300 mg group and the others, and only p-values <0.01 are shown. Viral loads were only reduced by higher doses at days 2 and 5, but not day 10, except for 900 mg. **(b)** The probability of rebound for different doses. The error bars on each column are 95% confidence intervals. **(c)** Examples of viral load trajectories assuming different doses on 4 modeled individuals with equivalent timing of therapy and untreated viral kinetics. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range.

888
889




890
891
892
893
894
895
896
897
898
899
900
901
902
903

Fig. 5. Early timing of therapy initiation is a key risk factor for viral rebound. In all simulations, the dose was 300 mg twice daily for five days. PEP = 0 to 1 day after infection, early = 1-3 days after symptom onset, intermediate = 3-5 days after symptom onset, and late = 5-10 days after symptom onset. **(a)** log₁₀ viral load at days 2, 5, and 10 after the treatment start day with different treatment durations. p-values were obtained by performing two-sided Mann-Whitney U-test. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range. **(b)** The probability of rebound for different treatment timing. The error bars on each column are 95% confidence interval **(c)** Samples of viral load trajectories assuming different treatment timing on 4 modeled individuals with equivalent untreated viral kinetics.



904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919

Fig. 6. Prolonging treatment duration limits rebound probability. In all simulations, treatment starts within the first 3 days post-symptoms and the dose was 300 mg twice daily. **(a)** log₁₀ viral load at days 2, 5, and 10 after the treatment start day with different treatment durations. p-values were obtained by performing two-sided Mann-Whitney U-test and only values <0.01 are shown. At day 10, the control group had equivalent viral loads to 2 days of treatment while 5 or 10 days of treatment significantly lowered viral load. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range. **(b)** The probability of rebound for different treatment durations. The probabilities of rebound after 15 and 20 days of treatment were zero. The error bars on each column are 95% confidence interval. **(c)** Samples of viral load trajectories assuming different treatment durations on 4 modeled individuals with equivalent timing of therapy and untreated viral kinetics. Prolonging therapy often avoids rebound.



920
921

922 **Fig. 7. Post-exposure prophylaxis requires more prolonged therapy than early**
923 **symptomatic therapy to avoid viral rebound. (a) probability of rebound and**
924 **(b) viral load at the end of the treatment as a function of treatment timing and**
925 **duration.**

926

927




Fig. 8. Early therapy preserves susceptible cells, limits refractory cells, does not eliminate all infected cells, and delays innate immune responses.

Simulations are performed using time since infection as a variable rather than based on symptoms as in prior figures to eliminate the confounding impact of variable incubation period. **(a)** The top row shows the viral load of all individuals (in grey) and the average viral load (in blue). The middle row shows a less substantial depletion of susceptible cells (S, in green) and a lower generation of refractory cells (R, in red) with earlier therapy. The infected cells (I) are shown in blue. The highlighted area around each line (not visible) shows the 95% confidence interval. The bottom row shows the rate of production of refractory cells, which likely represents innate immune responses per day. The biphasic immune response with a lower initial peak and a second one after the end of the treatment is observed with early therapy and is present to a lesser extent in day 4 treated individuals. The highlighted areas show 95% confidence intervals. **(b)** Ratios of susceptible (S) to refractory cells (R) at the end of the 5-day treatment for different timings of treatment. **(c)** Per cell production rate of refractory cells at the end of the 5-day treatment for different timings of treatment. In all box plots, the center line is the median; box limits are upper and lower quartiles; whiskers show a 1.5x interquartile range. p-values were obtained by performing two-sided Mann-Whitney U-test (*: $0.01 < p \leq 0.05$, **: $0.001 < p \leq 0.01$, ***: $0.0001 < p \leq 0.001$, ****: $0.00001 < p \leq 0.0001$).

928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952